Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD). It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

Renaissance is a US-based contract development and manufacturing organization (CDMO) for pharmaceutical and biotech companies. With over 20 years of experience in nasal sprays and sterile injectable dosage forms, we have an unparalleled track record of helping our clients from development through to commercial launch. Core Capabilities: - Aseptic fill-finish development and manufacturing (vials) - Unit-dose and bi-dose nasal spray development and manufacturing - Preserved and Non-preserved multi-dose nasal spray development and manufacturing - Analytical development & testing services - Spray characterization development & testing services - Formulation development & optimization - DEA Schedule I-V products From early-stage development through final production, Renaissance has the expertise and resources you need for success. Visit renpharm.com to learn more.

We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.

Since 1990 Specified Technologies Inc. (STI) is an industry leader in developing innovative fire protection systems that help stop the spread of fire, smoke, and hot gases. Specified Technologies Inc. has worked closely with the construction industry to create simple solutions to complex firestopping problems. STI has been at the forefront of developing the most advanced and cost-effective firestop solutions on the market, offering premium quality, superior performance, and best-in-class service, training, and support. Our SpecSeal® and EZ-Path® product lines are engineered to deliver powerful performance. Because our system designs are user-driven, they are easier to apply. The result is simply designed, outstanding fire protection systems which often result in lower installed costs. STI products and systems offer innovative firestop solutions for all types of new construction and retrofit applications. Since firestopping is our only business, we concentrate all our resources on providing the highest quality, fully tested, innovative firestopping solutions that are backed with over 1,300 UL® Classified systems; This is more than any firestop company in the world. STI is committed to supporting our customers by providing sustainable firestop solutions, management programs for firestop, treating them like partners, and by consistently adding value beyond the sale. Whether you are an architect, a contractor, or an installer…you can depend on STI to deliver knowledgeable advice, premium quality products, and the total firestop solution.

In 1959, entrepreneur Robert H. Dallas formed what was to become one of the larger privately-owned chemical companies in the United States. In 1989, a newly formed Dallas Group of America, Inc. was established as a spin-off and grew into a diversified manufacturer of basic and specialty chemicals. The Dallas Group produces the highest quality MAGNESOL® and DALSORB® synthetic magnesium silicates, ammonium chloride, ammonium sulfate, and lignosulfonates and serves customers in more than 100 countries. The company operates multiple manufacturing and packaging facilities in North America, China, and Europe. The Dallas Group’s laboratories are staffed with degreed chemists, engineers, and technicians performing more than 50,000 tests each year to ensure that all products and raw materials meet specifications for quality and purity. Selected staff routinely participate in the AOCS Approved Chemists Program and have been awarded Proficiency Program Winner status in AOCS’s NIOP Fats and Oils Program numerous times. Our production facilities are GMP-certified, ensuring that our products are consistently produced and controlled according to quality standards.

Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.

Cosette Pharmaceuticals is a US based, diversified pharmaceutical company with a proven topicals and dermatology portfolio and a growing branded pharmaceuticals business. We are fully integrated, with a deep focus on internal R&D, high quality manufacturing standards and commercial sales excellence. We continue to diversify and expand through strategic partnerships, acquisitions and internal R&D. Our highly experienced leadership team are busy writing the next, most ambitious chapter of our story. Building on a 100+ year heritage, their shared vision of innovation will leverage the expertise of more than 350+ team members, and infrastructure to create remarkable new opportunities for the patients and physicians we serve every day. Innovating every day.™

Piramal Critical Care (PCC), a business division of Piramal Pharma Limited (PPL) is one of the leaders in inhaled anesthetics and a global player in hospital generics. “Saving and improving patients’ lives” is much more than a purpose statement to us. We are motivated by our vision of commitment to delivering critical care solutions for patients and healthcare providers, while achieving sustainable and profitable growth for all the stakeholders. Piramal Critical Care maintains a wide presence across the US, Europe and more than 100 countries across the globe. Our product portfolio includes inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, injectable anti-infectives, oral therapy for Type I Gaucher and Niemann pick Type C disease, anticholinergic, plasma volume expander, non-depolarizing neuromuscular blocking agent, depolarizing skeletal muscle relaxant and an anxiolytic, sedative and pain medication. Our products include Sevoflurane, Desflurane, Isoflurane, Halothane, Gablofen® (Baclofen Injection), MITIGO™(Morphine Sulfate), Dipidolor® (Piritramide), Sublimaze® (Fentanyl Citrate), Rapifen® (Alfentanil Hydrochloride), Sufenta® (Sufentanil Citrate), Hypnomidate®(Etomidate), Ampicillin and Sulbactam for Injection, USP, Cefepime for Injection, USP, Ceftriaxone for Injection, USP, Linezolid Injection, Ampicillin for Injection, USP, Piperacillin and Tazobactam for Injection, USP, Yargesa™ (Miglustat), Glycopyrrolate, Haemaccel, Rocuronium Bromide Injection, Succinylcholine Chloride Injection, USP, Dexmedetomidine Injection, USP, Dexmedetomidine HCl in 0.9% Sodium Chloride Injection (RTU*) and Propofol- Lipuro emulsion for Injection or Infusion. PCC has strong manufacturing and process development experience. PCC has fully owned manufacturing facilities in Bethlehem, PA, USA and Digwal, India. Customer centricity is the cornerstone of our business. *RTU Ready to use

Recordati Rare Diseases Inc. (RRD) markets products to treat rare diseases. RRD is a member of the Recordati Group, which includes Recordati S.p.A., Orphan Europe, among other companies around the globe. The Recordati Group, which was established in 1926 currently employs more than 4,000 worldwide. The RRD mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. For more information, visit www.amarincorp.com. See our Community Guidelines: bit.ly/2L7xEW6

Spectrum Chemical Mfg. Corp. manufactures and distributes fine chemicals and laboratory products with quality and delivery you can count on every time. The Company’s major emphasis is on USP, NF, FCC, BP, EP, JP and ACS grade products, active pharmaceutical ingredients and controlled substances, excipients, dietary supplements, cosmetic ingredients, biochemicals, pre-made solutions, and a complete line of high-purity solvents for critical analytical applications. These products are available in laboratory research, scale-up and production quantities. Spectrum also provides US-based custom synthesis and contract manufacturing capabilities, including the custom synthesis of new chemical entities (NCE’s) and commercial cGMP manufacture of active pharmaceutical ingredients, DEA Controlled Substances (Schedules II-V) and their chemical intermediates. Spectrum is also a full-line distributor of laboratory supplies and equipment items featuring PerkinElmer’s complete line of consumables for GC, HPLC, IR, UV/VIS, AA, ICP, mass spectrometry and thermal analysis instrumentation. Combined with additional products from over 250 manufacturers of labware, consumables, lab equipment and appliances, Spectrum is truly a one-stop shopping destination with over 100,000 chemicals and lab equipment & consumable items available.

Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.